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Abstract
The current treatment paradigm for right sided infective endocarditis is rapidly 
evolving. The existing recommendations for right sided infective endocarditis 
include medical therapy with surgical therapy used in certain situations. Surgical 
therapy is based on the size of the vegetation, presence of infective complications 
and certain causative organisms as well the retention of intracardiac devices. 
Unfortunately, medical therapy alone is usually not enough to clear the infection, 
especially when intravenous drug use is associated as the etiology. Intravenous drug 
use is associated with a high rate of recidivism in tricuspid valve endocarditis. Even 
with indications for surgery, these patients present an ethical dilemma as most 
of these patients will re-infect their valves post-surgery. This often provides little 
option than for the surgeon to re-operate in a setting with a higher risk of mortality 
and morbidity. We present an evolving technique of percutaneous extirpation of 
vegetation, allowing for rapid clearance of endocarditis, less chance of failure of 
medical therapy with a lower risk profile for complication.
Keywords: tricuspid endocarditis, percutaneous treatment, cardiac implantable 
device endocarditis, CIDE, extirpation
1. Introduction
Endocarditis is defined as inflammation of the inner layer of the endocardium, 
usually involving the heart valves and or chambers of the heart, the valves being 
more commonly affected than the heart chambers [1]. Endocarditis is further 
categorized into non-bacterial thrombotic endocarditis (NBTE) or noninfectious 
endocarditis, and infectious endocarditis (IE) [2]. NBTE is rare and associated with 
malignancy and chronic inflammatory states such as systemic lupus erythematosus, 
rheumatoid arthritis, ANCA-vasculitis, burns, and sepsis [2, 3]. Conversely, IE 
is more common, with annual incidence of 3–10 cases per 100,000 people [4, 5]. 
It occurs due to bacterial and less commonly due to fungal infections [1, 4, 5]. 
Staphylococcus aureus is now the leading cause of IE, accounting for about 26.6% 
of all cases [4]. Staphylococci, streptococci (including the viridans group) and 
enterococci comprise about 80–90% of all cases of IE [4, 5]. The other 10–20% of 
cases are due culture negative endocarditis and fastidious organisms such bartonella 
species, brucella species, Coxiella burnetii, haemophilus species, Aggregatibacter 
actinomycetenomitans, Cardiobacterium hominis, Eikenella corrodens, Kingella kingae 
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and Tropheryma whipplei [5]. Endocarditis is characterized by lesions, known as 
vegetations. These vegetations follow endocardial injury where platelets and fibrin 
form a nidus which becomes secondarily infected by microorganisms circulating in 
the blood. (1) Endocarditis can involve both the right and left side of the heart and 
often can have differing causative organisms and etiologies. Left sided endocarditis 
can involve the aortic valve, mitral valve and in severe cases can involve the aorto-
mitral curtain causing damage to the electrical structures of the heart. Right sided 
endocarditis typically involves the valvular structures on the right side of the heart 
most commonly the tricuspid valve and less often the pulmonary valve. In addition, 
the right sided endocarditis may also involve foreign bodies that are typically found 
transversing the right atrium such as pacemaker leads, central lines.
2. Right sided infective endocarditis
Right sided Infective Endocarditis (RSIE) accounts for about 10% of all IE cases 
[6]. Typically, these patients are younger with fewer medical comorbidities and 
less underlying valve disease as compared to patients with left-sided IE [6]. RSIE 
involves both tricuspid valve endocarditis (TVE) and cardiac implantable device 
endocarditis (CIDE). RSIE is most frequently seen with intravenous drug use 
(IVDU). Other predisposing risk factors include use of central venous catheters, 
cardiovascular implanted electronic devices, congenital heart disease, prosthetic 
heart valves, and end-stage renal disease on hemodialysis [5, 6]. Mortality rate of 
RSIE is typically 5–15% [6]. The risk factors and independent predictors of death 
are age, Staphylococcus aureus infection, heart failure, embolic events and health 
care-associated IE [5].
2.1 Tricuspid valve endocarditis
2.1.1 Epidemiology
Ninety percent of RSIE involves the tricuspid valve, of which infection result-
ing from intravenous drug use (IVDU) constitutes approximately 30–40% of all 
tricuspid valve endocarditis cases. The incidence of tricuspid lesions in IVDU is 
approximately 50–65%, with a prevalence of about 2–5% per year [6]. With ongoing 
IVDU, IE reoccurs in about 28% of cases due to prior damage or replacement of the 
valve [6]. Staphylococcus aureus is the predominant causative organism in TVIE, just 
as in all types on of IE [4, 6]. The opioid epidemic over the last several years has seen 
an increase in patients with IVDU as subsequently an increase in TVE. Heroin abuse 
has more than doubled over the past decade along with TVE during the same period. 
A study by Wallen et al. showed a fivefold increase in surgical volume for tricuspid 
endocarditis from 2011 to 2017. In addition, the average age of patients seemed to 
decrease from 52.85 +/−19.6 years to 39.2 +/−12.9 over the same five-year period [7]. 
In addition, multiple other studies have reported an increase in tricuspid-related IE 
corresponding to an increase in IVDU during the same period [8–10].
2.1.2 Treatment and prognosis
As a whole, RSIE carries a good prognosis. TVIE clears in 70–85% of cases with 
antibiotic treatment alone. Non-operatively treated TVIE carries an in-hospital 
mortality of 7–11% [6]. Non operative treatment typically consists of 4–6 weeks 
of intravenous antibiotics. However, approximately 5–16% cases of RSIE will 
require surgical intervention [6]. Indications and timing for surgery are less clear 
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for RSIE than for left-sided infectious endocarditis (LSIE). According to the most 
recent AHA/ACC guidelines, surgery for native RSIE is indicated for patients with 
antibiotic failure, multi-drug-resistant organisms, tricuspid vegetations greater 
than 2 cm, embolic complications, or right-sided heart failure with poor response 
to diuretics [11, 12]. Most patients with infected prosthetic TV will require surgery, 
except in patients with unacceptable intra-operative mortality risk [6]. Surgery 
is less often performed for TV regurgitation due to IE, as it is more amendable to 
medical management and unlike aortic or mitral valve regurgitation, most patients 
can tolerate TV regurgitation up to a certain period [6]. Patients with isolated TVIE 
have an operative mortality between 0 and 15% and excellent survival. The post-
surgical in-hospital mortality for TVIE is less than 10% and long term post-surgical 
mortality for TVIE is less than 15%, but increased in the presence of additional risk 
factors such as continued intravenous drug abuse, hemodialysis, valve replacement, 
S. aureus, and vegetation greater than 20 mm [6].
2.1.3 Current surgical options
Over the years, various surgical options have been used in TVIE. Surgical 
options range from valve repair or replacement to the removal of the tricuspid valve 
leaflets and chordae tendinae without replacement (valvectomy). Valvectomy, 
essentially commits the patient to require surgical repair, but has been used with 
success to temporize a patient while fighting ongoing systemic infection [6]. 
According to a systematic review by Luc et al., the post-operative 30-day mortal-
ity, right heart failure, and recurrent endocarditis was the same with valvectomy 
compared to surgical valve replacement for endocarditis but with a slightly higher 
non-significant trend towards higher postoperative right heart failure and 30-day 
mortality [13]. Tricuspid reoperation rate, however, was higher in valvectomy 
(56%) versus valve replacement (14%) in addition to an increased likelihood of 
prolonged ventilation (40% vs. 26%) in the valvectomy group [13].
Tricuspid valvectomy can be a feasible option in patients with active ongoing 
IVDU, normal pulmonary pressure, normal biventricular heart function, high 
degree of valvular destruction and high risk of reoperation, recidivism and recur-
rence for infection [13, 14]. Valvectomy with valve replacement as a staged proce-
dure can allow patients to self-select in terms of their ability to maintain adequate 
follow-up, undergo detoxification and drug rehabilitation, optimize their social 
and financial situation, and demonstrate abstinence from IVDU prior to tricuspid 
valve replacement. However, valvectomy is largely falling out of favor due to the 
potential of severe right heart failure and the ventricularization of right atrial 
pressures [13, 15]. In patients with normal heart function pre valvectomy, severe 
right heart failure with symptoms of peripheral edema and ascites can occur within 
6–9 months post valvectomy [6]. Therefore, patient with elevated pulmonary artery 
pressure are therefore not candidates for complete valvectomy [6].
The preferred surgical procedure is that of repair, particularly because it adheres 
to the basic principles cited for the successful surgical treatment of infective 
endocarditis. These include aggressive and extensive debridement of vegetations; 
correction of defects that have developed; use of autologous tissue to avoid implan-
tation of artificial material [13, 16]. Most centers will prioritize valve repair prior to 
valve replacement or valvectomy [13].
2.1.4 Valve choice with replacement
Both bioprosthetic valves and mechanical valves have been used for valve 
replacement in TVIE. The gold standard anticoagulation after mechanical valve 
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replacement is warfarin. Warfarin is can be difficult to manage as levels are depen-
dent on patients’ variable vitamin K intake and requires frequent monitoring. 
Furthermore, problems with compliance with monitoring and anticoagulation 
therapy is more frequently seen in patients with IVDU and this population is also 
the most common to present with recurrent right-sided endocarditis and require 
surgery for valve replacement. With bioprosthetic valve replacement, only first 
three months of anticoagulation after replacement are required to prevent throm-
bosis, although this practice itself can be variable [17, 18]. This time frame allows 
for reendothelialization to the suture zone [17]. Due to decreased duration of 
anticoagulation, bioprosthetic valves are associated with lower rates of bleeding 
complications [19].
Another advantage of bioprosthetic valve replacement compared to mechanical 
valve, is the thrombosis risk. Obstruction of the tricuspid mechanical prosthesis 
due to thrombosis is 20 times more frequent than left-sided prosthetic valve 
thrombosis [17]. This is likely due to low flow state of the right heart compared to 
the left. Lastly, Patients with bioprosthetic valve replacement are still candidates 
for pacemaker and ICD placement as compared to mechanical valves [6]. Similarly, 
embolic events are more common with mechanical valves [19]. Ergo, prosthetic 
valve replacement may be a better option from this perspective. Mechanical 
tricuspid valve replacement may be beneficial from the durability perspective as 
they last longer than bioprosthetic valves [6, 19]. Previously average failure time 
for tricuspid bioprosthetic valve was 7 years [19]. However, the durability of new 
bioprosthetic valves have improved over the years as recent data suggest no dif-
ference in long term data between bioprosthetic and mechanical valves at 15 years 
[20]. Additionally, mitral homografts have been used in the tricuspid space but with 
limited experience and long-term data [21].
2.1.5 Percutaneous options for valve replacement
Percutaneous tricuspid valve replacement (PTVR) creates unique challenges 
as compared to the left side. One, the tricuspid annulus is large is size compared to 
the mitral annulus and can be further increased with right ventricular dilation. For 
large valve replacement, large caliber sheaths and large bore venous access must be 
obtained [22]. Only jugular and femoral veins can accommodate such large bores 
of up to 45 French [22]. Trans-atrial approach has been used in the past; however, 
this requires surgical expertise. Two, tricuspid valves are more difficult to anchor 
percutaneously as there is limited calcification and the structure itself is dynamic 
(changes in diameter in systole and diastole). Three, PTVR carries an increased risk 
post-procedural conduction defects just as with surgical repair [6, 21]. Frequently 
with percutaneous replacement the tricuspid annulus becomes stretched. This can 
cause a complete atrio-ventricular (AV) block, requiring pacemaker placement, due 
to proximity of the AV node and the bundle of His to the tricuspid valve. Similarly, 
proximity of the tricuspid valve to the right coronary artery, coronary sinus, vena 
cava create additional challenges with percutaneous placement and valve design 
[22]. Furthermore, patients with pacemaker or ICD devices are not great candidates 
for percutaneous tricuspid valve replacement as placement of a valve may dislodge 
leads. Lastly, there is very limited data on the percutaneously placed tricuspid 
valve replacement durability and more studies are necessary. Unlike, for surgical 
tricuspid valve replacement there are no guidelines regarding timing of percutane-
ous valve aortic valve replacement after infective endocarditis. Without surgical 
debridement or percutaneous debulking and with antibiotics use alone, there is a 
high theoretical reinfection risk of the new tricuspid valve placed using a percuta-
neous approach after endocarditis.
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2.2 Cardiac implantable device endocarditis
Cardiac implantable device endocarditis (CIDE) involves cardiovascular 
implantable electronic devices (CIED) which include permanent pacemakers 
(PPM), implantable cardiac defibrillators (ICD), and cardiac resynchronization 
systems (CRT). CIDE is diagnosed based on the presence of the following four 
criteria:
• Presence of a cardiac device;
• No other source of infection;
• A positive culture for typical causative agents from the pocket of the device or 
its leads; and
• Echocardiographic findings of vegetation on the tricuspid valve or at the end 
of the electrical lead [23].
Specifically, for CIDE diagnosis, the Duke criteria should be used. Patient pre-
sentation can be variable and can involve all or just a few symptom including fevers, 
rigors, anorexia, fatigue, local tissue inflammation. In addition, there may be 
possible purulent discharge, device exposure, focal pain that may help localize the 
primary site of infection. Other symptoms could be neurologic or cardiac consistent 
with embolic stroke, or symptoms of volume overload [23].
2.2.1 Epidemiology
Intracardiac device infections constitute approximately 10% of all endocarditis 
cases [24]. CIEDs have been implanted in patient as early as 1960s, but over the last 
two decades had significant increase in incidence. According to American Heart 
Association update, between 1997 and 2004, PPM placement increased by 19% and 
ICD placement increased by 60% [25]. Other studies quote an even higher increase 
of 30% for PPM and over 500% for ICDs [26]. In the United States greater than 
500,000 PPMs and ICDs are implanted per year with over 4 million implanted 
between 1993 and 2008 [27]. Notably, more patients who are elderly and those with 
many comorbidities have been receiving these devices [25]. In developed countries 
20–35% of CIEDs were placed in patients older than 80 years of age [25].
Over the years, changing the implantation site of ICD from abdomen (associated 
with 3.2% infection rate) to pectoral site (associated with 0.5% infection rate) ini-
tially decreased the incidence of device related infections [25]. Despite the innova-
tion in PPM and ICD technology together with better surgical technique, the rate of 
infections associated with cardiac devices has increased by 124–210% [25, 26]. About 
1.8–31.1 cases of CIED infection per 1000 device years has been reported for PPM 
and ICD devices and overall higher rates of infection with ICDs and CRTs [27]. This 
change is likely due to increased rate of CIED implantation in people over the age of 
65 and presences of major comorbidities such as renal failure, respiratory failure, 
heart failure and diabetes [26]. CIED infections are associated with up to 18% of 
morbidity and mortality and increase by 47% per decade hospital charges [26].
Early infection typically arises from device implantation [27]. With first time 
implantation the rate of CIED related infection is 0.5–1% and 1–5% with device 
replacement or upgrade [27]. CIED related infection can involve the bloodstream, 
the generator pocket, the leads, or endocardial structures [26, 27]. Late infection 
typically arises from patient poor health or other clinically significant processes. 
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Almqvist et al., further divides the spectrum of CIED infections into six different 
categories: early post-implantation inflammation, uncomplicated pocket infection, 
complicated pocket infection, definite CIED lead infection, possible CIED lead 
infection, CIED-associated endocarditis, and probable CIED infection [26].
2.2.2 CIED infection risk factors
Patients with chronic kidney disease, long-term corticosteroid use, presence of 
more than 2 pacing leads, diabetes mellitus, heart failure and oral anticoagulation 
are at higher risk for CIED infection [25, 26]. Use of preprocedural temporary pac-
ing, fever within 24 hours prior to implantation, blood stream infections, and early 
reintervention were also associated with higher risk of CIED infection [25]. Lower 
rates of CIED infection was associated with antibiotic perioperative prophylaxis 
new device placement, use of pectoral approach rather than abdominal or transtho-
racic approach, and device placement by a high-volume physician [25].
2.2.3 Pathogenesis and microbiology
Source of microorganisms often originate from the skin during the implantation 
of the electrical agent in the subcutaneous tissue, from the pocket in which the elec-
trical agent is placed, the tunnel that forms around the lead before its point of entry 
into the blood vessel or from bacteria unrelated to the CIED, which may be present in 
the form of a foreign body placed on or in contact with the endocardial tissue, or that 
applies pressure to the endocardial tissue and tricuspid valve [23, 27]. Alternatively, 
contamination of the CIED can occur at different stages or from various causes. This 
includes but is not limited to manufacturing or packaging, infection prior to or dur-
ing implantation, secondary to surgical site infection or via hematogenous seeding 
from a distant site or after erosion through the skin [24, 25, 27].
Physical and chemical properties such as electrostatic charge, surface tension 
and hydrophobicity of each device plays an important role in the interaction with 
bacteria and development of bacterial attachment and biofilm formation [23]. 
More hydrophobic surfaces such as polyvinyl chloride, polyethylene, silicone, latex 
and stainless steel are associated with higher microbial adherence [24]. Pathogens 
are more likely to adhere to irregular surfaces and may also adhere to the patient’s 
matrix proteins (fibrinogen, fibronectin and collagen) that coat the surface of an 
implanted device [25]. CIED infections are more likely to occur due to gram positive 
bacteremia than gram negative bacteremia [25]. Staphylococci species, especially 
coagulase negative staph, have a knack for adhesion to CIEDs via host matrix pro-
teins and to each other thus forming biofilms [24, 25]. Coagulase negative staphylo-
cocci comprise 42% of all PPM and ICD infections, followed by oxacillin sensitive 
S. aureus (25%), oxacillin resistant S. aureus (4%), with the remaining causative 
organisms being other gram positive cocci (4%), gram negative bacilli (9%), fungal 
(2%), polymicrobial (7%), and unidentified/culture negative (7%) [28].
2.2.4 The role of biofilm
Biofilm is a group of one or more microbial species firmly attached to a device sur-
face and each other and covered by extracellular polymeric matrix [24, 25]. This matrix 
provides a protective barrier and results in antibiotic resistance and extreme difficult 
of bacterial irradiation that frequently requires device explanation [24, 25]. Some 
bacteria are more adept to adhering to non-biological materials such as staphylococci.
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2.2.5 Treatment and prognosis
Antibiotics are generally empirically initiated after obtaining at least three 
sets of blood cultures. These usually consists of broad-spectrum intravenous 
antibiotics covering both gram-positive and gram-negative bacteria, including 
methicillin/oxacillin-resistant Staphylococcus aureus [29]. Antibiotic therapy alone 
without device removal, however, is associated with a 7 times increase in 30-day 
mortality [28]. Treatment of CIDE as recommended per the 2017 HRS Consensus 
Document include complete device and lead removal in addition to antibiotics [29]. 
Immediate system removal is associated with a 3 times decrease in 1-year mortality 
as compared to preliminary antibiotic treatment and delayed system removal [30]. 
Mortality rates in patients with endocarditis who had systems removed and anti-
microbial therapy are 18% or less compared with up to 66% on antibiotic therapy 
alone [27]. Multiple clinical studies have now demonstrated a 97.7% clinical success 
rate with hardware removal in addition to antibiotic therapy [30].
2.2.6 Duration of treatment
The start of antibiotic therapy duration is counted from the first day of nega-
tive blood cultures, therefore it is reasonable to obtain blood cultures every 24 to 
48 hours until they are negative [31]. If the patient requires surgery and the surgical 
cultures are negative, then the duration of therapy is still counted from the first 
day of negative blood cultures [31]. If surgical cultures are positive, then the start 
of antibiotic therapy duration occurs the next day, after the achievement of source 
control [31]. This applies to post device removal as well as some authors recommend 
obtaining new blood cultures 48–72 hours post device removal [26]. If the need for 
CIED remains in patients treated for bacteremia, negative blood cultures should be 
documented at least 72 hours prior to new device implantation [29]. Duration of 
treatment usually consists of 4–6 weeks of IV antibiotics, in addition to removal of 
CIED [29].
3. Evolving percutaneous options for treatment
Given that 10–15% of patients fail medical therapy, percutaneous treatment 
options as an adjunct to medical therapy have now started to become main-
stream. Specifically, the use of AngioVac device (AngioDynamics, Latham, 
New York) has begun to get traction because of its ease of use, low risk profile 
and ability to debulk the vegetation and prevent septic pulmonary emboli. The 
AngioVac system is a veno-venous extracorporeal system. The most common 
configuration is as a bilateral femoral venous platform or via the right internal 
jugular and femoral platform. The system mainly consists of a cannula and a 
circuit along with a trap, which captures the undesirable material. AngioVac 
is currently used in the setting of thromboembolic disease, particularly in the 
vena cava or the right atrium. Both the cannula and circuit are indicated for use 
in procedures requiring extracorporeal circulatory support for periods up to 
six hours for removal of fresh, soft thrombi or emboli. The cannula and circuit 
are designed to be used with off shelf pump, filter and reinfusion cannula. The 
device itself leverages the use of blood flow through a centrifugal pump to create 
negative pressure in order to extirpate undesirable intravascular material, such as 




The current iteration of the cannula is in its third generation. It is available in 
either a 180- or 20-degree angled tip (Figure 1). The cannula itself is radiopaque 
with a self-expanding nitinol tip which allows for visualization under fluoroscopic 
imaging. The tip is funnel shaped which allows for greater contact surface area of the 
unwanted material and the cannula shaft supported by a flat stainless-steel coiled wire 
within the catheter body to support greater pushability, kink resistance, and column 
strength. The cannula is further supported by a slide over sheath (Figure 2), which 
allows the user to maintain the desired angle needed to engage the unwanted material.
3.2 Circuit
The circuit consists of ½ inch tubing typically used for extracorporeal circula-
tion with the use of quick connectors which allow for greater efficiency and ease 
of use. The quick connector are rotating adapters that allows for rotation of the 
cannula independently without twisting or kinking the circuit tubing. In addition, 
the circuit has a built in Y-Adapter with touhy insert allowing for over-the-wire 
capability through a working side port (Figure 3). This allows the user to use up to a 
17 French adjunctive device alongside the cannula if needed.
Figure 2. 




Contemporary and Evolving Treatment of Tricuspid Endocarditis
DOI: http://dx.doi.org/10.5772/intechopen.95434
3.3 Pump
The pump used with this system can be any off the shelf centrifugal pump. The 
centrifugal pump leverages negative pressure with increase in flow rates to extirpate 
undesirable material into the trap. Typical flow rates are around 3-4 Liters/minute. 
Once the material is engaged, flows will almost always come down to zero, but the 
negative pressure of the pump circulating allows the material to be suctioned up 
into the cannula and subsequently into the circuit and trap. Cavitation can occa-
sionally occur but is well tolerated on the right side especially if the patient does 
not have a patent foramen ovale. When cavitation occurs, clamping the inflow and 
outflow and deairing the circuit is made simple due to the quick connectors.
3.4 Placement
As mentioned earlier, the AngioVac cannula can be used in the vena cava as well 
as the right atrium. It is not indicated for use in the pulmonary artery, but centers 
have used it in the right ventricle on occasion to extirpate vegetation or clot under-
neath the tricuspid valve. As centers have gained more experience with thrombo-
embolism mainly in the right atrium, more centers are now using AngioVac for 
vegetations particularly on the tricuspid valve [32–34]. Access is obtained usually 
percutaneously in both femoral veins or through the right internal jugular vein and 






The surgical indications for TVE are less clear than that of endocarditis involving 
the left side of the heart. Current indications for surgery include vegetations >2 cm, 
evidence of septic pulmonary emboli, methicillin resistant organism, fungal infections 
and structural deterioration causing severe tricuspid valve regurgitation and heart 
failure [21]. However, given the repeat IVDU in these patients a surgical treatment is 
less likely to last for long due to repeat episodes of TVE. More concerning is the poten-
tial of prosthetic valve endocarditis which almost always necessitates a reoperation. 
Surgeons often find themselves in an ethical dilemma when patients represent needing 
a reoperation, especially when they have failed a second or third time. The risk of 
reoperation steadily increases and at some point, the risks outweigh the benefits. 
Figure 4. 
AngioVac placement and configuration.
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However, a percutaneous option is more appealing due to its less invasive nature and 
the fact that it can be done multiple times without increasing the risk for the patient.
4. Current data
4.1 Percutaneous valve debulking in tricuspid valve endocarditis
Although vast data for the use of percutaneous valve debulking (PTVD) is rare, 
there are some retrospective data available. George et al., look at a review of 33 
consecutive patients over 40 months who were declined traditional surgical manage-
ment for TVE. Procedural success was defined as the removal of >1 cm of particulate 
and/or the ability to removal additional particulate. Patients were young with a vast 
majority being positive for IVDU (73%) with staphylococcal species being the most 
common causative agent. (75%). The average size of the tricuspid vegetation was 
2.1 + 0.7 cm. More than 75% of patients had clearance of bacteremia within 48 hours 
of the procedure. Roughly 43.5% of patients however had worsening of their tricus-
pid regurgitation [32]. The same group also compared PTVD to valve replacement in 
a retrospective study which showed that the 1-year mortality was unchanged between 
the two cohorts, with the PTVD cohort having a shorter hospital length of stay [33].
A recent multicenter retrospective review showed at in 89 patients, 70% of 
patients had complete clearance of bacteremia within 48 hours of the proce-
dure with only one patient requiring surgery for severe TR and heart failure. 
Surprisingly, the TR was unchanged in most patients (60%) and improved in 20% 
and worsened in 20%. The group of patient who had worsening of their TR were 
those who was on the borderline of mild–moderate and moderate–severe TR [34].
4.2 AngioVac in CIDE
Recent data from Starck et al. in 101 patients undergoing lead extraction with 
vegetation showed low risk and possible survival benefit when PTVD was com-
bined with lead extraction [35]. Extraction was performed with either mechanical, 
laser or traction alone in the setting of a femoral to femoral venous configuration of 
AngioVac. This resulted in a theoretical reduction of septic pulmonary emboli with 
low intraprocedural complication rate. Overall, thirty-day mortality was 3% which 
was due to severe sepsis.
5. Conclusion
RSIE is increasing particularly due to the incidence of patients with CIEDs 
and IVDU particularly due to the opioid epidemic (7–10). Medical management 
alone is these groups of patients leads to medical failure and can lead to further 
complications such as septic pulmonary emboli. Surgical intervention in TVE is 
associated with higher risk of recurrent infection, thromboembolic and bleeding 
complications and reoperation with valve replacement [6]. In addition, contempo-
rary series have shown that valve repair is preferred over replacement especially in 
IVDUs [6, 36, 37]. In addition to current recommendations, the use of percutaneous 
aspirational techniques provide a unique and effective way to treat these patients. 
These techniques are evolving and may become standard of care involving a multi-
disciplinary approach and avoid the need for surgical intervention at the time of 
presentation and potentially allow for a greater chance of needing of having a repair 
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